Clinical Trial

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Study acronym: NPC1-AD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology
Protocol Amendment History 3 changes
critical Phase changed: Phase 1/2 -> Phase 2 2026-05-09
critical Primary endpoint(s) modified 2026-05-09
critical Recruitment opened 2026-04-18
Trial Details
NCT Number NCT07236190
Lead Sponsor Massachusetts General Hospital
Conditions Alzheimer Disease, Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
Enrollment 40 participants
Start Date 2026-04-01
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-08